Shopping Cart
Remove All
Your shopping cart is currently empty
TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,720 | 3-6 months | 3-6 months | |
| 50 mg | $3,780 | 3-6 months | 3-6 months | |
| 100 mg | $4,900 | 3-6 months | 3-6 months |
| Description | TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2. |
| Targets&IC50 | NEP:9.2(pIC50), AT1:(pKi)8.9 |
| In vitro | TD-0212 exhibits improved dual AT1/NEP inhibition activity and may present a reduced angioedema risk compared to dual ACE/NEP inhibition. |
| In vivo | In renin-dependent and non-dependent hypertension models, TD-0212 can lower blood pressure, similar to omapatrilat and the combination of AT1 receptor antagonist and NEP inhibitor. |
| Molecular Weight | 641.67 |
| Formula | C30H35F4N3O6S |
| Cas No. | 1073549-11-7 |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (194.80 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.